2005
Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study
Modi W, Scott K, Goedert J, Vlahov D, Buchbinder S, Detels R, Donfield S, O'Brien S, Winkler C. Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study. Genes & Immunity 2005, 6: 691-698. PMID: 16177829, DOI: 10.1038/sj.gene.6364258.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdolescentAdultAllelesBlack or African AmericanChemokine CXCL12Chemokines, CXCChildCohort StudiesDisease ProgressionFemaleGene FrequencyHaplotypesHIV InfectionsHIV-1HumansLongitudinal StudiesMaleOdds RatioPolymorphism, Single NucleotideRisk FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsSDF-1 geneCohort studySingle nucleotide polymorphismsAfrican AmericansOnly natural ligandSingle disease outcomesX4 HIV-1HIV-1 infectionAIDS Cohort StudyRisk of infectionMACS cohortDisease outcomeHIV-1Epidemiological studiesSDF-1Significant associationChemokine genesInfectionRs1801157Natural ligandProgressionHaplotype analysisCommon haplotypeCXCR4CohortCommunity Incidence of Hepatitis B and C among Reincarcerated Women
Macalino G, Vlahov D, Dickinson B, Schwartzapfel B, Rich J. Community Incidence of Hepatitis B and C among Reincarcerated Women. Clinical Infectious Diseases 2005, 41: 998-1002. PMID: 16142665, DOI: 10.1086/432936.Peer-Reviewed Original ResearchConceptsHepatitis B virusIncidence of HBVHCV infectionHepatitis BHepatitis C virus infectionC virus infectionDrug treatment servicesDrug-dependent personsIncident infectionsHIV testingBaseline prevalenceB virusCommunity incidenceIncidence rateVirus infectionTreatment servicesDrug useDrug dependenceInfectious diseasesInfectionSerum samplesIncidenceStudy periodWomenHCV
2004
MICA and recovery from hepatitis C virus and hepatitis B virus infections
Karacki P, Gao X, Thio C, Thomas D, Goedert J, Vlahov D, Kaslow R, Strathdee S, Hilgartner M, O'Brien S, Carrington M. MICA and recovery from hepatitis C virus and hepatitis B virus infections. Genes & Immunity 2004, 5: 261-266. PMID: 15029237, DOI: 10.1038/sj.gene.6364065.Peer-Reviewed Original ResearchConceptsHepatitis C virusHepatitis B virus infectionChronic hepatitis BB virus infectionHepatitis BC virusVirus infectionMICA polymorphismNatural killer cellsHBV infectionHCV infectionHepatitis CKiller cellsViral clearanceViral persistenceT cellsStudy populationMICA allelesSignificant associationInfectionFurther investigationVirusAssociationPersonsDifferential distribution
2003
Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans
Duggal P, An P, Beaty T, Strathdee S, Farzadegan H, Markham R, Johnson L, O'Brien S, Vlahov D, Winkler C. Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes & Immunity 2003, 4: 245-250. PMID: 12761559, DOI: 10.1038/sj.gene.6363950.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaLate-stage HIV-1 infectionAfrican AmericansHIV-1 infectionMedian survival timeSIV infectionCarinii pneumoniaChemokine receptorsAIDS progressionPrimary coreceptorSurvival timeK polymorphismInitial infectionCXCR6Receptor allelesInfectionProgressionSingle nucleotide polymorphismsDeathK genotypesAIDSCoreceptorNucleotide polymorphismsGenetic influencesAllele frequenciesFactors Associated With Human Herpesvirus Type 8 Infection in an Injecting Drug User Cohort
Bernstein K, Jacobson L, Jenkins F, Vlahov D, Armenian H. Factors Associated With Human Herpesvirus Type 8 Infection in an Injecting Drug User Cohort. Sexually Transmitted Diseases 2003, 30: 199-204. PMID: 12616135, DOI: 10.1097/00007435-200303000-00004.Peer-Reviewed Original ResearchConceptsHHV-8 seroprevalenceRisk factorsHHV-8Human herpesvirus type 8 infectionLarger body mass indexHuman herpesvirus type 8Drug user cohortHHV-8 seropositivityInjection drug useBody mass indexMultivariate logistic regressionCross-sectional studyDrug user populationGenital wartsMass indexGeneral populationDrug useSeroprevalenceIndirect immunofluorescenceLogistic regressionIDUsInfectionType 8User cohortSexual behaviorEffects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression
Mulherin S, O'Brien T, Ioannidis J, Goedert J, Buchbinder S, Coutinho R, Jamieson B, Meyer L, Michael N, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Theodorou I, Vlahov D, Rosenberg P. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression. AIDS 2003, 17: 377-387. PMID: 12556692, DOI: 10.1097/00002030-200302140-00012.Peer-Reviewed Original ResearchConceptsHIV-1 disease progressionHIV-1 seroconvertersCCR5-Delta32CCR2-64ICourse of infectionDisease progressionLower riskChemokine receptor gene polymorphismsCox proportional hazards modelHIV-1 infectionIndividual patient dataCCR2-64I alleleProportional hazards modelReceptor gene polymorphismsCCR2-64I.Disease courseSurvival benefitHazards modelGene polymorphismsCCR5-Δ32Significant protectionAIDSPatient dataInfectionSeroconverters
2001
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.
Ioannidis J, Rosenberg P, Goedert J, Ashton L, Benfield T, Buchbinder S, Coutinho R, Eugen-Olsen J, Gallart T, Katzenstein T, Kostrikis L, Kuipers H, Louie L, Mallal S, Margolick J, Martinez O, Meyer L, Michael N, Operskalski E, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Stewart G, Theodorou I, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury J, O'Brien T. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Annals Of Internal Medicine 2001, 135: 782-95. PMID: 11694103, DOI: 10.7326/0003-4819-135-9-200111060-00008.Peer-Reviewed Original ResearchConceptsHIV-1 infectionCCR2-64I alleleHIV-1 RNA levelsHIV-1 disease progressionDevelopment of AIDSIndividual patient dataCCR5-Delta32Decreased riskDisease progressionProtective effectLower HIV-1 RNA levelsRNA levelsProspective cohort studyCase-control studyClear protective effectStrong protective effectChemokine receptor genesRandom-effects modelCCR2-64ICohort studyStudy entryCertain chemokinesAIDSInfectionProgressionDynamics of SEN Virus Infection among Injection Drug Users
Wilson L, Umemura T, Astemborski J, Ray S, Alter H, Strathdee S, Vlahov D, Thomas D. Dynamics of SEN Virus Infection among Injection Drug Users. The Journal Of Infectious Diseases 2001, 184: 1315-1319. PMID: 11679921, DOI: 10.1086/324001.Peer-Reviewed Original ResearchConceptsInjection drug usersSEN virusDrug usersSEN virus infectionSENV-H DNASENV-H infectionPosttransfusion hepatitisSENV infectionViral clearancePolymerase chain reactionViral persistenceClinical significanceVirus infectionInfectionSerum samplesChain reactionReinfectionVirusDNA virusesHepatitisClearanceImprovement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy
Semba R, Shah N, Vlahov D. Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 315-319. DOI: 10.1097/00042560-200104010-00003.Peer-Reviewed Original ResearchFactors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City
Diaz T, Des Jarlais D, Vlahov D, Perlis T, Edwards V, Friedman S, Rockwell R, Hoover D, Williams I, Monterroso E. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. American Journal Of Public Health 2001, 91: 23-30. PMID: 11189819, PMCID: PMC1446499, DOI: 10.2105/ajph.91.1.23.Peer-Reviewed Original ResearchConceptsInjection drug usersYoung adult injection drug usersAdult injection drug usersHepatitis B virusDrug usersHCV infectionPrevalent hepatitis C virus infectionHepatitis C virus infectionYoung injection drug usersAnti-HCV positivityPrevalent HCV infectionPrevalent hepatitis CC virus infectionHIV serologyHCV antibodiesHepatitis CB virusVirus infectionDrug treatmentDrug useHCVNew York CitySex practicesInfectionUpper Manhattan
2000
HTLV-II and Bacterial Infections Among Injection Drug Users
Safaeian M, Wilson L, Taylor E, Thomas D, Vlahov D. HTLV-II and Bacterial Infections Among Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 483-487. DOI: 10.1097/00042560-200008150-00014.Peer-Reviewed Original ResearchConceptsHTLV-II infectionInjection drug usersHTLV-IIBacterial pneumoniaInfective endocarditisOdds ratioBacterial infectionsDrug usersChart reviewConditional logistic regression methodsSelf-reported skinStandardized chart reviewOngoing cohort studyCase-control studyEnzyme-linked immunosorbentCohort studyHIV statusResults PrevalenceSkin abscessesRisk factorsControl studyEndocarditisInfectionImmunofluorescent assayPneumoniaHTLV-II and Bacterial Infections Among Injection Drug Users
Safaeian M, Wilson L, Taylor E, Thomas D, Vlahov D. HTLV-II and Bacterial Infections Among Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 483-487. DOI: 10.1097/00126334-200008150-00012.Peer-Reviewed Original ResearchHTLV-II infectionInjection drug usersHTLV-IIBacterial pneumoniaInfective endocarditisOdds ratioBacterial infectionsDrug usersChart reviewConditional logistic regression methodsSelf-reported skinStandardized chart reviewOngoing cohort studyCase-control studyEnzyme-linked immunosorbentCohort studyHIV statusSkin abscessesRisk factorsControl studyEndocarditisInfectionImmunofluorescent assayPneumoniaLogistic regression methodDeterminants of the Quantity of Hepatitis C Virus RNA
Thomas D, Astemborski J, Vlahov D, Strathdee S, Ray S, Nelson K, Galai N, Nolt K, Laeyendecker O, Todd J. Determinants of the Quantity of Hepatitis C Virus RNA. The Journal Of Infectious Diseases 2000, 181: 844-851. PMID: 10720503, DOI: 10.1086/315314.Peer-Reviewed Original ResearchConceptsHCV RNA levelsHepatitis C virus RNAHIV-negative personsC virus RNAHCV RNARNA levelsLower HCV RNA levelsSerum HCV RNA levelsHepatitis B infectionInjection drug useHuman immunodeficiency virusVirus RNAVirologic factorsB infectionHCV infectionImmunodeficiency virusNeedle sharingBlood levelsPositive personsDrug useYounger ageInfectionEquivalents/Additional researchPerson variabilityIncreased Frequency of Overdose Deaths Among HIV-Infected Injection Drug Users
Vlahov D, Tang A, Lyles C, Rezza G, Thomas D, Cohn S, Macalino G, Stambolis V, Nelson K. Increased Frequency of Overdose Deaths Among HIV-Infected Injection Drug Users. Addiction Research & Theory 2000, 8: 311-326. DOI: 10.3109/16066350009009518.Peer-Reviewed Original ResearchInjection drug usersCause-specific mortalityHTV infectionOverdose deathsDrug usersUninfected personsPerson-time techniquesOverall mortality rateFrequency of AIDSOnset of AIDSCorrelates of deathMedian ageHIV serostatusPerson yearsExcess riskDrug overdoseMortality ratePoisson regressionRecord searchUnderlying causeInfectionMortalityDeathAIDSBaseline
1999
Prevalence of Lower Genital Tract Infections Among Human Immunodeficiency Virus (HIV)—Seropositive and High-Risk HIV-Seronegative Women
Cu-Uvin S, Hogan J, Warren D, Klein R, Peipert J, Schuman P, Holmberg S, Anderson J, Schoenbaum E, Vlahov D, Mayer K, Group F. Prevalence of Lower Genital Tract Infections Among Human Immunodeficiency Virus (HIV)—Seropositive and High-Risk HIV-Seronegative Women. Clinical Infectious Diseases 1999, 29: 1145-1150. PMID: 10524955, DOI: 10.1086/313434.Peer-Reviewed Original ResearchConceptsHIV-seronegative womenGenital tract infectionLower genital tract infectionHuman immunodeficiency virusTract infectionsBacterial vaginosisImmunodeficiency virusHigh-risk HIV-seronegative womenLower Genital Tract InfectionsRisk HIV-seronegative womenHuman papilloma virus infectionHIV-seropositive womenPapilloma virus infectionHigh-risk womenNeisseria gonorrhoeae infectionChlamydia trachomatis infectionHIV Epidemiology Research StudySimilar HIVSeropositive womenGonorrhoeae infectionBaseline visitTrachomatis infectionCandidal vaginitisVirus infectionInfectionSelf-Reported Bacterial Infections Among Women with or at Risk for Human Immunodeficiency Virus Infection
Flanigan T, Hogan J, Smith D, Schoenbaum E, Vlahov D, Schuman P, Mayer K. Self-Reported Bacterial Infections Among Women with or at Risk for Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1999, 29: 608-612. PMID: 10530455, DOI: 10.1086/598641.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCD4 cell countImmunodeficiency virus infectionBacterial infectionsRecent pneumoniaVirus infectionCell countHIV-negative womenHIV-seropositive womenUrinary tract infectionInjection drug useLogistic regression analysisSelf-reported pneumoniaCross-sectional analysisSeronegative womenTract infectionsHIV infectionDrug useLifetime historyInfectionPneumoniaMajor causeWomenRegression analysisCell categoriesRE: “HIGH RATES OF HIV INFECTION AMONG INJECTION DRUG USERS PARTICIPATING IN NEEDLE EXCHANGE PROGRAMS IN MONTREAL: RESULTS OF A COHORT STUDY”
Garfein R, Lyerla R, Jones T, Nakashima A, Monterroso E, Vlahov D. RE: “HIGH RATES OF HIV INFECTION AMONG INJECTION DRUG USERS PARTICIPATING IN NEEDLE EXCHANGE PROGRAMS IN MONTREAL: RESULTS OF A COHORT STUDY”. American Journal Of Epidemiology 1999, 150: 325-325. PMID: 10430240, DOI: 10.1093/oxfordjournals.aje.a010009.Peer-Reviewed Original ResearchClass II HLA Alleles and Hepatitis B Virus Persistence in African Americans
Thio C, Carrington M, Marti D, O'Brien S, Vlahov D, Nelson K, Astemborski J, Thomas D. Class II HLA Alleles and Hepatitis B Virus Persistence in African Americans. The Journal Of Infectious Diseases 1999, 179: 1004-1006. PMID: 10068598, DOI: 10.1086/314684.Peer-Reviewed Original ResearchConceptsHBV persistenceHBV infectionImmune responseClass II HLA typingHepatitis B virus (HBV) persistenceHepatitis B virus infectionClass II HLA allelesB virus infectionPersistent HBV infectionClass I associationsHost immune responseClass II allelesAfrican American cohortAntigen presentationVirus infectionHLA typingHLA allelesVirus persistenceTwo-locus haplotypesAmerican cohortThree-locus haplotypesClass IIHLA complexInfectionClass IHIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 years old
Carneiro M, Fuller C, Doherty M, Vlahov D. HIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 years old. Drug And Alcohol Dependence 1999, 54: 83-86. PMID: 10101620, DOI: 10.1016/s0376-8716(98)00142-2.Peer-Reviewed Original ResearchConceptsInjection drug usersInjection drug useRisk behaviorsDrug usersDrug useCross-sectional studyRates of HIVHigh-risk behaviorsAge of initiationHIV infectionHIV prevalenceFirst injectionWide age rangeAverage ageNew initiatesHygiene practicesAge rangeAgeRecruitment techniquesInjectionYearsHIVInitiationInfectionPrevalence
1998
Diversification of Subtype E Human Immunodeficiency Virus Type 1 env in Heterosexual Seroconverters from Northern Thailand
Wang Z, Lyles C, Beyrer C, Celentano D, Vlahov D, Natpratan C, Markham R, Khamboonruang C, Nelson K, Yu X. Diversification of Subtype E Human Immunodeficiency Virus Type 1 env in Heterosexual Seroconverters from Northern Thailand. The Journal Of Infectious Diseases 1998, 178: 1507-1511. PMID: 9780276, DOI: 10.1086/314441.Peer-Reviewed Original ResearchConceptsHIV-1 infectionAsymptomatic HIV-1-infected subjectsHIV-1 subtype EHIV-1-infected subjectsHuman Immunodeficiency Virus Type 1 EnvSubtype E HIVC2-V3 regionHuman immunodeficiency virusHIV vaccine developmentInjection drug usersE HIVRecent seroconvertersImmunodeficiency virusSubtype ESeroconvertersHIV-1Drug usersVaccine developmentMolecular epidemiologyEnv sequencesInfectionEnvNorthern ThailandHIVBaltimore